Clinical Trials on Pancreatic Cancer Resectable in South Africa

Total 3450 results

SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

Cardiotoxicity | Recurrent Breast Carcinoma | HER2/Neu Positive | Metastatic Malignant Neoplasm in the Brain | Stage IV Breast Cancer AJCC v6 and v7

United States, Korea, Republic of, Puerto Rico, Saudi Arabia
National Cancer Institute (NCI)

Recruiting

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction

Esophageal Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Sarcoma | Metastatic Cancer

United States, Canada, Australia, Puerto Rico
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
zr Pharma & GmbH
Foundation Medicine

Terminated

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)

Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Muscle Invasive Bladder Cancer | Ureter Carcinoma | Renal Pelvis Carcinoma | Urinary Bladder Carcinoma | Urethra Carcinoma

United States, Spain, France, Italy, Germany, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Lung Adenocarcinoma | Lung Large Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Minimally Invasive Lung Adenocarcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7 | Lung Squamous Cell Carcinoma | Lung Adenocarcinoma, Mixed Subtype

United States
Southwest Oncology Group
National Cancer Institute (NCI); Roche-Genentech

Completed

S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States
Velindre NHS Trust

Unknown

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

Lung Cancer | Thromboembolism

United Kingdom
Cell Genesys

Terminated

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States, France, Belgium, Canada, United Kingdom, Sweden, Netherlands, Germany
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Head and Neck Cancer

United States, Canada, Saudi Arabia
University Medical Center Groningen
NRG Oncology; Dutch Cancer Society

Recruiting

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III (GROINSS-VIII)

Vulvar Cancer | Sentinel Lymph Node | Lymph Node Metastases

United States, Netherlands
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

Breast Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Drug/Agent Toxicity by Tissue/Organ

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Active, not recruiting

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer (S1216)

Prostate Cancer

United States
Hoffmann-La Roche

Terminated

A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer

Endometrial Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

Pain | Breast Cancer | Musculoskeletal Complications

United States
Eli Lilly and Company

Completed

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Poland, Belgium, Canada, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Metastatic Cancer | Melanoma (Skin)

United States
Novartis Pharmaceuticals

Completed

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

Cancer

France, Australia, United States, Canada, United Kingdom
Daiichi Sankyo
AstraZeneca; Daiichi Sankyo Co., Ltd.

Active, not recruiting

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Breast Cancer

United States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Korea, Republic of, United Kingdom, Spain, Belgium, Singapore, Canada, Netherlands, Australia
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States, Canada
Adaptimmune
GOG Foundation

Recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Ovarian Cancer

United States, Spain, France, United Kingdom, Canada
Novartis Pharmaceuticals

Completed

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Breast Cancer

United States
Cell Genesys

Terminated

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Prostate Cancer

United States, France, United Kingdom, Italy, Germany, Netherlands, Canada, Poland, Sweden, Belgium
Pfizer

Active, not recruiting

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Taiwan, Australia, United Kingdom
Sumitomo Pharma Switzerland GmbH

Recruiting

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)

Prostate Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Cervical Cancer

Cervical Cancer

United States, Canada
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Psychological Impact of Cancer

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile

Thyroid Cancer

United States, Canada, Germany, Korea, Republic of, Spain, France, Australia, Belgium, Denmark, Israel, Italy, Poland, Romania, Russian Federation, Sweden, United Kingdom
IGM Biosciences, Inc.

Recruiting

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Sarcoma | Acute Myeloid Leukemia | Colorectal Cancer | Solid Tumor | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chondrosarcoma | Small Lymphocytic Lymphoma

United States, Korea, Republic of, France, Spain, Australia
Radiation Therapy Oncology Group
National Cancer Institute (NCI)

Completed

Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer

Head and Neck Cancer | Skin Reactions Secondary to Radiation Therapy

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Hoffmann-La Roche

Completed

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB)

Gastric Cancer

Austria, Belgium, Brazil, Canada, China, Croatia, Finland, Hungary, Italy, Korea, Republic of, Mexico, Poland, Spain, Turkey, United States, Kazakhstan, Peru, Russian Federation, Switzerland, Taiwan, Thailand, Germany, Japan, Malaysia, ... and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer (CheckMate 7DX)

Prostate Cancer

Romania, United States, Israel, Russian Federation, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Puerto Rico, Singapor... and more
Achieve Life Sciences
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY)

Prostate Cancer

United States, Belgium, Canada, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Spain, United Kingdom
Karyopharm Therapeutics Inc
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042)

Endometrial Cancer

United States, Belgium, Spain, Israel, Australia, Italy, Georgia, Ireland, Greece, Germany, Czechia, Slovakia, Canada, Hungary
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Memorial Sloan Kettering Cancer Center
Bayer

Recruiting

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Prostate Cancer

United States, Netherlands, Spain, Brazil
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer

Ovarian Carcinoma

United States
Spectrum Pharmaceuticals, Inc

Completed

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Metastatic Cancer

France, United States, Canada, Belgium, Italy, Australia, United Kingdom, Germany, Hungary
AstraZeneca

Active, not recruiting

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) (CASPIAN)

Small Cell Lung Carcinoma Extensive Disease

Germany, United States, Poland, Taiwan, Turkey, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, China, Netherlands, Spain, Israel, Ukraine, Austria, France, Bulgaria, Romania, Argentina, Slovakia
AbbVie

Completed

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)

Small Cell Lung Cancer

United States, Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Poland, Portugal, Romania, Russian... and more
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Prostate Cancer

United States
Five Prime Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

Gastric Cancer

United States, Spain, China, Italy, Korea, Republic of, Portugal, Taiwan, Japan, Turkey, France, Hungary, Thailand, Germany, Poland, Australia, Belgium, Romania, United Kingdom
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, New Zealand, Germany, Australia, United States, Poland, Spain, Chile, Sweden, France, Italy
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Obesity | Fatigue | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Neurotoxicity Syndrome

United States, Korea, Republic of
Galera Therapeutics, Inc.

Completed

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Oral Mucositis

United States, Puerto Rico, Canada

Clinical Trials on Pancreatic Cancer Resectable in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations